Melevodopa
 | |
| Systematic (IUPAC) name | |
|---|---|
| methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate | |
| Clinical data | |
| Identifiers | |
| 7101-51-1 | |
| N04BA04 | |
| PubChem | CID 23497 |
| ChemSpider |
21968  |
| UNII |
M30686U4X4 |
| KEGG |
D07304 |
| Chemical data | |
| Formula | C10H13NO4 |
| 211.215 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Melevodopa is a dopaminergic agent. It is the methyl ester of levodopa. It is used in tablet form as an effervescent prodrug with 250 times higher water solubility compared to tablet levodopa.[1]
See also
References
- ↑ Patrick Hickey and Mark Stacy (2011). "Available and emerging treatments for Parkinson’s disease". Drug Des Devel Ther 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||